Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-137 in healthy subjects
NCT02334982Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of TAK-137 in schizophrenia and major depressive disorder (MDD) (7 arms), sponsored by Takeda. Primary endpoints: Treatment-Emergent Adverse Events up to 30 days, Abnormal Safety Laboratory Findings up to 30 days and 1 more. Started Jun 2013; status: completed.
02
Drugs
TAK-137
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02334982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334982.